Regeneron (REGN) Tops Q2 EPS by $8.11, Sales Pounce Consensus

Regeneron (NASDAQ: REGN) reported Q2 EPS of $25.80, $8.11 better than the analyst estimate of $17.69. Revenue for the quarter came in at $5.14 billion versus the consensus estimate of $3.89 billion.

• Second quarter 2021 revenues increased 163% to $5.14 billion versus second quarter 2020 including $2.76 billion attributable to REGEN-COVTM(2); revenues excluding REGEN-COV(1)(2) increased 22%
• Second quarter 2021 EYLEA® U.S. net sales increased 28% versus second quarter 2020 to a record $1.42 billion
• Second quarter 2021 Dupixent® global net sales(3), which are recorded by Sanofi, increased 59% to $1.50 billion versus second quarter 2020
• Second quarter 2021 GAAP diluted EPS was $27.97 and non-GAAP diluted EPS(1) was $25.80
• FDA updated REGEN-COV Emergency Use Authorization (EUA) with lower dose, subcutaneous administration, and post-exposure prophylaxis
• REGEN-COV Phase 3 RECOVERY trial in hospitalized patients with severe COVID-19 met primary outcome
• Reported that Dupixent significantly improved itch and hives in patients with chronic spontaneous urticaria, marking the fifth disease to show positive pivotal results
• Phase 3 trial of Libtayo® combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer

"Regeneron had outstanding performance in the second quarter during which we delivered to the U.S. government the entire order for our COVID-19 antibody cocktail and recognized record global sales from our EYLEA and Dupixent franchises," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "We continue to advance Dupixent\'s potential to help new patient groups, with recent positive Phase 3 data in chronic spontaneous urticaria and additional late-stage read-outs expected later this year in prurigo nodularis, eosinophilic esophagitis, and pediatric atopic dermatitis. With today\'s positive Phase 3 results in combination with chemotherapy in non-small cell lung cancer, Libtayo yet again demonstrates its potential to be a leading checkpoint inhibitor. We also progressed our genetics medicines platform, with landmark clinical data alongside our collaborator Intellia using a CRISPR therapeutic and the discovery of a promising new obesity target from the Regeneron Genetics Center."

For earnings history and earnings-related data on Regeneron (REGN) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• L3Harris Technologies (LHX) Tops Q1 EPS by 15c; raises guidance
• Business First Bancshares, Inc. (BFST) Misses Q1 EPS by 7c